ArticleInternational urogynecology journal2026
The Effect of Midurethral Slings on Overactive Bladder Medication Use in Women with Mixed Urinary Incontinence.
Article in International urogynecology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and hypothesisMixed urinary incontinence (MUI), characterized by both stress urinary incontinence (SUI) and urgency urinary incontinence (UUI), significantly impacts quality of life. Despite evidence suggesting that midurethral sling (MUS) procedures might improve overactive bladder (OAB) and UUI symptoms, it remains unclear whether discontinuation of OAB medications is appropriate in women with MUI undergoing MUS. We aimed to evaluate whether MUS placement changes the need for pharmacological OAB treatment postoperatively.
methodsThis retrospective cohort study included women with MUI who underwent MUS placement between 2017 and 2023 at a single academic center with at least 6 months of follow-up. Concomitant pelvic organ prolapse surgery or hysterectomy was allowed. Patients were stratified by preoperative OAB medication use. The primary outcome was postoperative OAB treatment trajectories, categorized as initiation, continuation, escalation, or discontinuation. Secondary analyses evaluated factors associated with postoperative initiation and continuation.
resultsA total of 617 women had MUI and underwent MUS placement (mean age 59.3 ± 12.8 years; body mass index 30.2 ± 6.4 kg/m
conclusionsPostoperative OAB treatment trajectories were heterogeneous, with most patients remaining stable, whereas a subset required initiation, escalation, or discontinuation of therapy.
Indexed as
Identifiers
42550182What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.